The BioWorld Insider Podcast
By BioWorld
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by BioWorld
Category: Life Sciences
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 2
Reviews: 0
Episodes: 35
Description
One-on-one with medical innovators: Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us for a new conversation.
| Episode | Date |
|---|---|
|
Mark McKenna storms back with Mirador and eyes the development landscape
|
Apr 23, 2024 |
|
Biopharma execs seek to avoid pain points in AI integration
|
Apr 16, 2024 |
|
Six biopharma executives consider a tough 2023 and are hopeful for a better 2024
|
Dec 11, 2023 |
|
AI: driving drug development from effective to remarkable
|
Sep 06, 2023 |
|
The struggle is real: The first half of 2023 was an uphill climb
|
Aug 16, 2023 |
|
The biosimilars challenge to Humira revs up
|
Jul 20, 2023 |
|
Preventing opioid overdoses with a smart patch
|
Jun 05, 2023 |
|
Better times ahead for the biopharma sector? Could be, the new numbers say
|
Apr 24, 2023 |
|
Radiopharmaceuticals: The next big disrupter?
|
Apr 05, 2023 |
|
Cambrian carves out a new niche as it works to keep people from getting sick
|
Feb 21, 2023 |
|
Rethinking obesity: Fitness may be more directly linked to health than weight
|
Jan 30, 2023 |
|
Looking ahead to 2023: CEOs contemplate the new normal
|
Dec 05, 2022 |
|
Psychedelic evolution: Mindset Pharma looks to change mental health treatment
|
Sep 21, 2022 |
|
$1B+ biopharma deals keep values afloat, even amid muted volume
|
Sep 08, 2022 |
|
Extending the human lifespan
|
Jul 18, 2022 |
|
New therapies vie to change the fatal course of amyotrophic lateral sclerosis
|
Jun 03, 2022 |
|
Biopharma’s correction? 2022 1Q investments are both up and down
|
May 02, 2022 |
|
Who advises the CDC on big COVID decisions?
|
Feb 23, 2022 |
|
Long COVID: Potentially the next public health crisis
|
Feb 14, 2022 |
|
What happens when your inventor is an artificial intelligence?
|
Dec 14, 2021 |
|
Another record year for biopharma financings bodes well for 2022
|
Dec 09, 2021 |
|
Aduhelm’s hard lessons and what it means for other Alzheimer’s drugs
|
Dec 09, 2021 |
|
Supply Chain Geeky: Managing through the challenges of COVID-19 with an eye to what’s at stake
|
Dec 09, 2021 |
|
Regulatory Gemish: COVID-19’s big impacts on the FDA and beyond
|
Dec 09, 2021 |
|
Reality check: How did industry develop COVID-19 vaccines and drugs so fast?
|
Oct 26, 2021 |
|
Merck’s new COVID-19 pill will save lives, but at what price?
|
Oct 18, 2021 |
|
Newly approved cervical cancer drug Tivdak gives patients a new option
|
Sep 24, 2021 |
|
DNA vaccines: a better path to taming the pandemic?
|
Sep 17, 2021 |
|
Rising to the COVID-19 challenge, clinical trials evolve
|
Sep 02, 2021 |
|
A ‘Revolution’ in drugging the undruggable hits a speed bump but motors on
|
Aug 20, 2021 |
|
As dementia cases grow, biomarkers and new therapies key to unlocking treatment
|
Jul 30, 2021 |
|
As biopharma deals keep pace, M&A volumes languish
|
Jul 09, 2021 |
|
Iteos brings Glaxosmithkline a third checkpoint-targeting antibody in a $2B deal
|
Jun 16, 2021 |
|
Finally, a new medicine for Alzheimer’s disease
|
Jun 10, 2021 |
|
The BioWorld Insider Podcast - trailer
|
Jun 04, 2021 |